Poonam A. Arora
Long/short equity, value, research analyst, biotech

Epizyme: Undervalued Rare Asset With Outsized Potential

Investment Thesis

Epizyme (NASDAQ:EPZM) is an oncology focused biotechnology company. Its drug development platform is based on epigenetics, the science of reversible gene expression. The company's lead drugs EPZ-5676 and EPZ-6438 are currently undergoing Phase I development. The agents represent a novel class of inhibitors that target epigenetic proteins called histone methyl transferaces (HMTs). Both EPZ-5676 and EPZ-6438 are backed by substantial scientific literature showing that for each drug the associated HMT protein is a valid target in the indications under study. In addition, in preclinical studies, both compounds were successful at inhibiting the HMT targets and reversing the epigenetic factors that triggered oncogenesis. However, as in the case of all biotechnology, translation of preclinical data to humans...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details